Novartis AG (NYSE:NVS) Shares Purchased by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC boosted its holdings in shares of Novartis AG (NYSE:NVS) by 1.5% during the 4th quarter, HoldingsChannel reports. The firm owned 14,661 shares of the company’s stock after purchasing an additional 213 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Novartis were worth $1,427,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Greenleaf Trust lifted its position in Novartis by 1.1% during the 4th quarter. Greenleaf Trust now owns 17,793 shares of the company’s stock worth $1,731,000 after acquiring an additional 192 shares during the period. Journey Strategic Wealth LLC lifted its position in Novartis by 4.3% during the 4th quarter. Journey Strategic Wealth LLC now owns 2,893 shares of the company’s stock worth $281,000 after acquiring an additional 118 shares during the period. Capital Insight Partners LLC lifted its position in Novartis by 10.2% during the 4th quarter. Capital Insight Partners LLC now owns 29,669 shares of the company’s stock worth $2,887,000 after acquiring an additional 2,737 shares during the period. Independence Bank of Kentucky raised its position in Novartis by 218.7% during the 4th quarter. Independence Bank of Kentucky now owns 9,382 shares of the company’s stock worth $913,000 after buying an additional 6,438 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Novartis during the 4th quarter worth $1,092,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. StockNews.com cut Novartis from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 31st. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets boosted their target price on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Novartis has a consensus rating of “Hold” and a consensus price target of $123.38.

Novartis Stock Up 0.0 %

Shares of NYSE:NVS opened at $105.51 on Wednesday. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92. The stock’s fifty day simple moving average is $100.14 and its 200-day simple moving average is $108.41. The company has a market capitalization of $215.65 billion, a P/E ratio of 17.94, a P/E/G ratio of 1.51 and a beta of 0.58.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.79%. As a group, equities research analysts forecast that Novartis AG will post 8.34 earnings per share for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.